Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Anti-microbial Agents and Antibiotic Lock Therapy), By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.62 Billion
CAGR (2026-2031)	5.63%
Fastest Growing Segment	Retail Pharmacies
Largest Market	North America
Market Size (2031)	USD 2.25 Billion

Market Overview

The Global Catheter Related Bloodstream Infection Market will grow from USD 1.62 Billion in 2025 to USD 2.25 Billion by 2031 at a 5.63% CAGR. The Global Catheter Related Bloodstream Infection Market comprises infection prevention and treatment solutions, including antimicrobial catheters, antibiotic locks, and site securement devices designed to mitigate pathogens associated with vascular access. The primary drivers propelling this market include the rising prevalence of chronic diseases requiring long-term hospitalization and the expanding geriatric population susceptible to hospital-acquired conditions. Furthermore, heightened regulatory mandates penalizing healthcare facilities for preventable infection rates compel the adoption of specialized sterilization and catheter technologies.

However, the market faces a significant challenge regarding the high cost of premium antimicrobial catheters compared to standard options, which limits adoption in cost-sensitive healthcare settings. This barrier is compounded by strict reimbursement policies that place the financial burden of treating hospital-acquired infections on medical facilities. Highlighting the persistent clinical need for effective solutions, according to the International Nosocomial Infection Control Consortium, in 2024, the pooled mean central line-associated bloodstream infection rate among pediatric intensive care patients was 5.37 episodes per 1,000 catheter days.

Key Market Drivers

The Introduction of Novel Catheter Lock Solutions and Therapies is critically influencing the market by providing advanced alternatives to traditional saline or heparin flushes, specifically addressing the clinical need to salvage infected devices rather than removing them. These innovative therapies are gaining traction as healthcare providers seek to reduce the morbidity and logistical complexity associated with central venous catheter replacement. The efficacy of such next-generation solutions is reshaping treatment protocols; according to Citius Pharmaceuticals, May 2024, in the 'Phase 3 Trial of Mino-Lok Antibiotic Lock Solution', the therapy demonstrated an overall treatment success rate of 57.1% in patients with catheter-related bloodstream infections compared to 37.7% in the control arm. This performance validates the shift toward high-value pharmacological interventions that actively suppress microbial colonization and improve long-term patient outcomes in critical care settings.

The Implementation of Stringent Infection Control Mandates serves as a primary regulatory force, compelling hospitals to invest in comprehensive prevention bundles and surveillance technologies to avoid financial penalties. Regulatory bodies are increasingly linking reimbursement to safety performance, driving the adoption of standardized catheter care protocols and advanced securement devices. The impact of these rigorous standards is evident in recent national data; according to The Leapfrog Group, November 2024, in the 'Fall 2024 Hospital Safety Grade', average central line-associated bloodstream infection scores decreased by 38% since the fall of 2022. Despite the clinical success of these mandates, the market faces cost pressures associated with compliance and premium product acquisition. According to CorMedix Inc., in 2024, the company established a wholesale acquisition cost of $249.99 per vial for its newly approved antimicrobial catheter lock solution, illustrating the significant financial investment required to integrate these advanced therapeutic safeguards.

Download Free Sample Report

Key Market Challenges

The Global Catheter Related Bloodstream Infection Market faces a distinct obstacle regarding the prohibitive cost of premium antimicrobial catheters compared to standard vascular access devices. While these advanced solutions offer enhanced pathogen protection, their elevated price creates a significant barrier for healthcare facilities managing restricted budgets. This financial friction is intensified by reimbursement structures that impose strict penalties for hospital-acquired conditions but often fail to provide adequate funding to cover the upfront expense of premium preventative technologies. Consequently, cost-sensitive procurement departments frequently opt for standard catheters, substituting expensive device-based solutions with rigorous, labor-intensive sterility protocols to meet regulatory safety standards.

This purchasing behavior directly restricts market revenue growth by limiting the adoption volume of high-margin antimicrobial products. Medical facilities may bypass expensive innovations if they can achieve required safety outcomes through process improvements and standard bundle compliance alone. Highlighting the effectiveness of these alternative containment strategies, according to The Leapfrog Group, in 2024, central line-associated bloodstream infections decreased by 38% over the last two years across surveyed hospitals. This significant reduction suggests that facilities are effectively controlling infection rates through current measures, potentially diminishing the perceived commercial necessity for investing in higher-cost catheter technologies.

Key Market Trends

The Expansion of Infection Prevention Solutions into Home Healthcare Settings is reshaping market dynamics as care delivery shifts from acute hospital environments to ambulatory and domiciliary models. This transition is driven by the clinical necessity to reduce long-term hospitalization costs and minimize nosocomial exposure, fostering a high demand for vascular access devices and sterility products optimized for non-clinical users. Consequently, infusion service providers are witnessing substantial growth, validating the commercial viability of advanced home-based care protocols. According to Option Care Health, October 2025, in the 'Third Quarter 2025 Earnings Call', the company reported net revenue of $1.435 billion, representing a 12.2% increase over the prior year, a surge attributed to the accelerated migration of infusion therapies to the home setting.

The Utilization of AI-Driven Digital Surveillance and Data Analytics is simultaneously emerging as a transformative force, enabling healthcare facilities to automate the complex detection of catheter-related pathogens. By integrating machine learning algorithms with electronic health records, institutions can rapidly identify infection clusters and streamline reporting compliance, significantly reducing the administrative burden on infection preventionists. This technological integration not only enhances diagnostic accuracy but also drastically cuts the time required for case reviews. According to Oxford Academic, November 2025, in the study 'Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections', AI-assisted surveillance review required a median of 14 minutes per case compared to 25 minutes for expert review, demonstrating the significant efficiency gains available through algorithmic monitoring.

Segmental Insights

The Retail Pharmacies segment is recognized as the fastest-growing category in the Global Catheter Related Bloodstream Infection Market. This expansion is principally driven by the strategic transition of patient care from acute hospital settings to home-based healthcare. As medical professionals prioritize reducing hospital stays to lower operational costs and minimize exposure to hospital-acquired infections, a growing number of individuals require long-term catheter management for conditions such as dialysis or chemotherapy at home. This trend has generated substantial demand for accessible oral antibiotics and maintenance supplies at retail outlets, directly propelling the segment’s accelerated development.

Regional Insights

North America maintains a dominant position in the global catheter-related bloodstream infection market, driven by a well-established healthcare infrastructure and heightened awareness of hospital-acquired conditions. The region’s market strength is supported by stringent initiatives from organizations such as the Centers for Disease Control and Prevention, which emphasize strict protocols for infection control. Additionally, the concentrated presence of key medical device manufacturers accelerates the availability and adoption of antimicrobial solutions. This continuous focus on regulatory compliance and patient safety ensures that North America remains the primary revenue generator in the global sector.

Recent Developments

• In September 2024, BD (Becton, Dickinson and Company) released new clinical data regarding the efficacy of its needle-free connectors in infection prevention. The study results indicated that the company's connectors featuring a solid external access surface were associated with a significantly decreased risk of central line-associated bloodstream infections compared to devices without this design feature. The research highlighted that these specific connectors also contributed to a reduction in central venous catheter intraluminal blood occlusions, thereby potentially lowering the need for additional medical interventions and reducing associated healthcare costs.
• In July 2024, CorMedix Inc. commenced the commercial shipments of DefenCath (taurolidine and heparin) to outpatient dialysis clinics and vascular access centers in the United States. This strategic move followed the implementation of a specific reimbursement coding decision by the Centers for Medicare & Medicaid Services. DefenCath is distinguished as the sole FDA-approved antimicrobial catheter lock solution designed to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis via a central venous catheter. The product had previously become available for inpatient use earlier in the year.
• In July 2024, Teleflex Incorporated established the Teleflex Center for Antimicrobial Protection as a new strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, this initiative was launched to combat the spread of infections caused by multidrug-resistant organisms and to reduce the incidence of complications such as central line-associated bloodstream infections. The center aims to function as a resource for healthcare providers and institutions by offering advanced educational support, partnership opportunities, and access to the company’s portfolio of antimicrobial catheter technologies and vascular access innovations.
• In May 2024, Citius Pharmaceuticals, Inc. announced positive topline results from its pivotal Phase 3 clinical trial of Mino-Lok, an antibiotic lock solution engineered to salvage infected central venous catheters. The study met its primary endpoint, demonstrating a statistically significant improvement in the time to catheter failure for patients treated with Mino-Lok compared to those receiving a clinician-directed antibiotic lock solution. The research indicated that the therapy was well-tolerated and could potentially establish a new standard of care for treating catheter-related bloodstream infections by preserving the catheter rather than requiring its removal and replacement.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

By Treatment Type	By Source of Infection	By Distribution Channel	By Region
Anti-microbial Agents and Antibiotic Lock Therapy	Coagulase-negative Staphylococcus S. Aureus Enteric Gram-negative Bacilli Yeasts Enterococci & Streptococci Pseudomonas and Others	Hospital Pharmacies Retail Pharmacies and Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Catheter Related Bloodstream Infection Market, By Treatment Type:

• Anti-microbial Agents and Antibiotic Lock Therapy

• Catheter Related Bloodstream Infection Market, By Source of Infection:

• Coagulase-negative Staphylococcus
• S. Aureus
• Enteric Gram-negative Bacilli
• Yeasts
• Enterococci & Streptococci
• Pseudomonas
• and Others

• Catheter Related Bloodstream Infection Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• and Online Pharmacies

• Catheter Related Bloodstream Infection Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE